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monthly injections of the long-acting androgen testo sterone undecanoate were associated with a very low rate of pregnancy in partners of treated men. the treatment regimen was well-tolerated, with no clinically significant adverse effects, and suppression of spermatogenesis was reversible after cessation of the drug.
almost since the introduction of female hormonal contraceptives in the 1960s, efforts have been underway to develop ana logous methods of male hormonal contra ception. testo sterone injections can effec tively inhibit spermatogenesis in most healthy men by suppressing pituitary secretion of folliclestimulating hormone and luteinizing hormone. low concentrations of these two hor mones deprive the testes of the signals required for spermatogenesis, leading to marked suppression of sperm production over a period of 10-12 weeks. a number of factors make a hormonal approach to male contraception appealing to both clinicians and patients. such factors include universal reversibility after cessation of testosterone treatment and the fact that >90% of treated men exhibit suppression of sperm production to levels associated with a very low risk of pregnancy. in addition, hormonal approaches to contraception exploit established drugs that have a long track record of safety in the treatment of men with hypogonadism.
Gu and colleagues 1 enrolled 1,045 Chinese men with proven fertility in a multi center, open-label, phase iii trial of monthly injections of 500 mg testo sterone un decanoate. Couples continued to use contra ception for the first 6 months of treatment (the suppression phase). if the man's sperm of gonadotropins, but not genetic variation in the gonadotropin or androgen-receptor genes, might relate to an individual's ability to suppress spermato genesis in response to male hormonal contraception. 3 these data reported by Gu et al. corroborate the very high efficacy of male hormonal contraceptive observed in small studies previously conducted in China. 4 Furthermore, the data reinforce those achieved internationally by the wHo using weekly injections of testo sterone enanthate, 5, 6 and in trials of testo sterone combined with a progestin. 7 even if the 19 pregnancies that occurred during the suppression phase are included in the overall rate of failure for testosterone undecanoate, this approach remains superior to the use of condoms (the only other truly reversible form of male contra ception), the failure rate of which approaches 15% per annum. 8 in terms of safety, no clinically significant adverse events were reported during the study. 18 men (~0.3%) discontinued the treatment during the efficacy phase, con cen tration had dropped to <1 million per ml of ejaculate, the couple was instructed to discontinue other methods of contraception and rely only on the testosterone injections (the efficacy phase). treatment was stopped after 24 months and a 12-month recovery phase followed. the study, therefore, provides a large database with which to judge the efficacy, safety, toler ability and reversi bility of this hormonal approach to male contraception. in terms of efficacy, 43 men (4.8%) failed to suppress spermatogenesis to <1 million sperm per ml of ejaculate, a level judged to be a reasonable goal for male hormonal contraceptives. 2 19 preg nancies occurred during the initial 6-month suppression phase, which suggests that improved counseling might be required for men who opt to use hormonal contraception. 855 men who attained suppres sion of spermato genesis entered the efficacy phase; nine preg nancies (~1%) occurred during this phase of the trial. six of these nine preg nancies occurred when sperm concentrations in men who had previously achieved suppression 'rebounded' to >1 million per ml of ejaculate. By contrast, the remaining three pregnancies occurred despite the fact that sperm concentrations remained below this threshold, which demon strates that pregnancy is possible even when male contra ceptive methods suppress sperm production to extremely low levels.
when the 1% failure rate is combined with the 5% of men who did not suppress spermatogenesis to <1 million sperm per ml of ejaculate-and, therefore, did not enter the efficacy phase of the study-the overall failure rate of the treatment regimen used by Gu et al. was 6%. serum concentrations www.nature.com/nrendo news & views presum ably as a result of adverse effects, which included change in libido (five men), skin rashes (five men), worsening of acne (three men), increased blood pressure (two men), fear of injections (two men), and injection-related fever (one man). in addition, around 4% of the participants complained of tender ness at the injection site, but none dis continued treatment for this reason. other common adverse effects that were noted, but did not result in discontinuation, included acne (77 men), severe cough after the injection (22 men), and change in mood or behavior (eight men). Participants' mean body weight increased by 1 kg during the course of the study, whereas testes volume decreased by 15%. minor changes in clinical laboratory values were recorded, and included a 7% increase in mean hemoglobin levels and decreases in the mean levels of total cholesterol, HDl cholesterol and lDl cholesterol (21%, 23% and 29%, respectively). no changes were observed in the levels of prostate -specific antigen or biochemical assessments of liver or kidney function.
in terms of tolerability, 312 men withdrew from the study: nonsuppressors (43 men), adverse events (18 men), lost to follow-up (93 men), change in contraception (43 men), requested with drawals (20 men), missed injections (40 men), rebound of spermatogenesis (10 men), pregnancy (nine men), and other reasons (36 men). the continuation rate was, therefore, >85%-a level higher than that associated with condom use, 9 although this figure must be interpreted with caution. men enrolled in this study were willing to have monthly intramuscular injections, and such men are not likely to be representative of the population as a whole. in terms of reversibility, sperm count had returned to normal in all but one man by the end of follow-up. this indivi dual apparently developed epididy mitis during the study, which was thought to be unrelated to the treatment regimen.
the study by Gu and colleagues demonstrates the very good efficacy, safety, toler ability and reversibility of monthly testo sterone undecanoate for male hormonal contra ception. nevertheless, it seems unlikely that this particular regi men will receive regula tory approval in China. additional studies of male hormonal contra ception are underway, most notably a large, international trial co sponsored by the wHo and the us-based Contraceptive research and Develop ment (ConraD) program.
10 this study will enroll 400 couples who will use a combination of injections of testo sterone undecanoate and norethi sterone enan thate every 8 weeks-a regimen demon strated to have a high degree of efficacy in previous small trials. 10 Future goals of research into male hormonal contra ceptives are to develop either an oral pill or an injectable agent that can be used every 2-3 months. such work is hoped to eventu ally bring the dream of male hormonal contra ception to fruition.
